DRACO
DRACO (Double-stranded RNA Activated Caspase Oligomerizer) is an experimental antiviral therapeutic approach designed to target and eliminate cells infected by viruses. The concept was developed by researchers at the Massachusetts Institute of Technology (MIT) and aims to provide a broad-spectrum antiviral treatment.
Mechanism of Action[edit]
DRACO works by combining elements of the body's natural defense mechanisms against viral infections. It utilizes a protein that can detect the presence of double-stranded RNA (dsRNA), a molecular pattern associated with viral infections. Upon detection of dsRNA, DRACO triggers apoptosis, or programmed cell death, in the infected cell, thereby preventing the virus from replicating and spreading to other cells. The key components of DRACO include:
- A dsRNA-binding domain that recognizes and binds to dsRNA.
- A caspase recruitment domain (CARD) that activates the apoptotic pathway.
Development and Research[edit]
The initial development of DRACO was led by Dr. Todd Rider at MIT. Early studies demonstrated that DRACO could effectively target and kill cells infected by a wide range of viruses, including influenza, dengue virus, and rhinovirus. These studies were conducted in vitro (in cell cultures) and in vivo (in animal models).
Potential Applications[edit]
DRACO has the potential to be developed into a treatment for various viral infections, including:
Challenges and Future Directions[edit]
Despite its promising potential, DRACO faces several challenges before it can be used as a therapeutic in humans. These challenges include:
- Ensuring the specificity of DRACO to avoid off-target effects and damage to healthy cells.
- Optimizing delivery methods to effectively target infected cells in the human body.
- Conducting extensive clinical trials to establish safety and efficacy in humans.
Related Pages[edit]
See Also[edit]
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99


W8MD Medical Weight Loss, Sleep and Medspa offers physician-supervised medical weight loss programs: NYC medical weight loss Philadelphia medical weight loss
Affordable GLP-1 Weight Loss ShotsAffordable GLP-1 Weight Loss Shots
Budget GLP-1 injections NYC (insurance & self-pay options) Popular treatments:
- Semaglutide starting from $29.99/week
- Tirzepatide starting from $45.00/week
✔ Most insurances accepted for visits ✔ Prior authorization support when eligible
Start your physician weight loss NYC journey today:
📍 NYC: Brooklyn weight loss center 📍 Philadelphia: Philadelphia weight loss center
📞 Call: 718-946-5500 (NYC) | 215-676-2334 (Philadelphia)
Tags: Affordable GLP1 weight loss NYC, Wegovy NYC, Zepbound NYC, Philadelphia medical weight loss
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
